GILD  Gilead Sciences Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

151.00B

Vuru Grade

76.45/100

Current Price

$101.38
-1.96 (-1.90%)

Growth Price

$107.39
Undervalued by 5.93%

Stability Price

$42.59
Overvalued by 57.99%

Company Metrics

  • 13.79 P/E
  • 6.18 P/S
  • 10.03 P/B
  • 7.35 EPS
  • 43.15% Cash ROIC
  • 1.76 Cash Ratio
  • 0 / 0% Dividend
  • 11.90M Avg. Vol.
  • 1.49B Shares
  • 151.00B Market Cap.

Company Description

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amph...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

What Could Possibly Go Wrong With Gilead Sciences Inc. Stock?
Motley Fool - 12 hours ago
In particular, I think the advice to prepare to be wrong is wise. With this in mind, I picked one of the stocks I personally own, Gilead Sciences (NASDAQ: GILD ) , to examine in order to identify how things could go awry. What could possibly go wrong ...
Morningstar: Gilead Sciences To Grow Its Hepatitis C Market - Benzinga
Credit Suisse Rating on Gilead Sciences, Inc. (NASDAQ:GILD) - Tricity State
Insider Selling : Gilead Sciences, Inc., Tesla Motors Inc, Wells Fargo & Co ...
Bidness ETC - 12 hours ago
Bidness Etc reports on the latest insider selling activity at Gilead Sciences, Inc. (NASDAQ:GILD), Tesla Motors Inc (NASDAQ:TSLA), Wells Fargo & Co (NYSE:WFC), and Yelp Inc (NYSE:YELP).
Gilead Sciences Reminds Me Of Apple Circa June 2013 (GILD)
Seeking Alpha - Apr 15, 2015
The recent pause in the appreciation of shares is likely to be temporary given their cheap valuations, and the company's stranglehold on two key markets and increasing free cash flow. In many ways, the stock of Gilead reminds me of where Apple was in ...
Gilead Sciences, Inc. (GILD) To Rule The Hepatitis C Market In 2015 ... - Bidness ETC
Gilead Sciences Inc. (NASDAQ:GILD) Will Dominate the Hepatitis C Market in ... - WallStreet.org
Gilead Is A Cash Generation Monster (GILD)
Seeking Alpha - Apr 16, 2015
Gilead Sciences (NASDAQ:GILD) is not only the biggest of the Four Horsemen of Biotech by market capitalization, revenue, and earnings, but it is also the biggest generator of free cash flows.
Prescription Data Offers Insight Into Gilead Sciences, Inc. Sales
Smarter Analyst - Apr 8, 2015
Gilead Sciences, Inc. (NASDAQ:GILD) received new data from IMS Health about the breakdown of its drug prescriptions.
Following Gilead Sciences, Inc., Which Biotech Will Pay a Dividend Next? - Motley Fool
Here's Why The Recent Drop In Gilead Sciences, Inc. (GILD) Stock Price Is ... - Bidness ETC
Is Gilead Sciences Inc. About to Crater Before Our Very Eyes?
Motley Fool - Mar 29, 2015
Gilead Sciences' (NASDAQ: GILD ) stock has been something of an enigma for biotech investors of late. Despite a 122% increase in revenue last year due primarily to the launch of its hepatitis C drugs Sovaldi and Harvoni, strong growth prospects going ...
Better Dividend Stock: AbbVie or Gilead Sciences, Inc.?
Motley Fool - Mar 23, 2015
AbbVie (NYSE: ABBV ) and Gilead Sciences (NASDAQ: GILD ) are two dividend-paying healthcare companies that perhaps underscore these issues best.
Which Dividend Paying Stock is Better: Gilead Sciences (NASDAQ:GILD) or ... - WallStreet.org
Amgen, Inc., Gilead Sciences, Inc., Biogen Inc, Celgene Corporation: Is A ...
ETF Daily News - Apr 14, 2015
Individual biotechnology stocks are also leaving the Nasdaq Composite in the dust. The chart below shows the one-year performance of Celgene (NASDAQ:CELG), Biogen (NASDAQ:BIIB), Gilead (NASDAQ:GILD) and Amgen (NASDAQ:AMGN).
Should Gilead Sciences, Inc. Be Worried By Achillion Pharmaceuticals?
Motley Fool - Apr 1, 2015
When it comes to treating hepatitis C, there's no bigger player than Gilead Sciences (NASDAQ: GILD). Thanks to recent launches of its pan-genotype HCV drug Sovaldi and its genotype 1 therapy Harvoni, Gilead Sciences is dominating the indication, with ...
Maxim Backs Gilead Sciences Inc Following Hep C Drug Approval in Japan - Smarter Analyst
Here's Why We Believe Gilead Sciences, Inc. (GILD) Stock Will Bounce Back - Bidness ETC
Fueled by Gilead Sciences, Inc's Hepatitis C Drugs, US Drug Spending Surged ...
Bidness ETC - Apr 14, 2015
The most expensive among these hepatitis C treatments is Harvoni from Gilead Sciences, Inc. (NASDAQ:GILD), which costs $94,500 for the complete 12-week treatment; the cost per pill of Harvoni comes down to $1,125, which has been hailed as extremely ...
Prescription drug spending jumps 13 percent to record $374 billion in 2014 - San Angelo Standard Times
IMS: US prescription drug spending jumped 13 pct. in 2014 - Boston Herald